Scleroderma
MONDO:0019340Scleroderma is a rare autoimmune connective tissue disorder characterized by abnormal hardening of the skin and, sometimes, other organs. It is classified into two main forms: localized scleroderma and systemic sclerosis (SSc), the latter comprising three subsets; diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc) and limited SSc (lSSc).
Also known as: scleroderma, scleroderma (disease)
339 clinical trials for this condition and its sub-types, 47 tagged with Scleroderma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Scleroderma
-
Systemic sclerosis 261 trials · 295 incl. sub-types
6 sub-types
- Diffuse scleroderma 82 trials
- Diffuse cutaneous systemic sclerosis 30 trials
- Pulmonary systemic sclerosis 27 trials
- Limited cutaneous systemic sclerosis 2 trials Sub-types →
- Limited systemic sclerosis 0 trials
- Scleroderma, familial progressive 0 trials
-
Localized scleroderma 14 trials · 15 incl. sub-types
2 sub-types
- Linear scleroderma 1 trial
- Lipodermatosclerosis 1 trial
-
Neonatal scleroderma 0 trials
Most studied deeper sub-types
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New antibody drug aims to halt Scleroderma's damage
Disease control OngoingThis Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can online therapy help scleroderma patients manage daily life?
Symptom relief OngoingThis pilot study tests whether a personalized online occupational therapy program is feasible and helpful for adults with scleroderma. Twenty-four participants in Spain will either receive eight online therapy sessions over four weeks plus usual care, or usual care alone. The stu…
Sponsor: Universidad de Zaragoza • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can an online class sharpen your mind with scleroderma?
Symptom relief OngoingThis study tests an 8-week online group program designed to help people with scleroderma improve their thinking skills and overall well-being. Researchers will compare participants who take the program right away to those on a waitlist. The goal is to see if the program boosts me…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New ultrasound technique could improve how we monitor scleroderma in kids
Knowledge-focused By invitation onlyThis study looks at whether a special ultrasound called elastography can measure changes in skin stiffness in children with localized scleroderma (morphea). The goal is to find a better, non-invasive way to track how well treatment is working. About 20 children and teens will be …
Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused CancelledThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC